A Phase I Single Centre, Randomized, Double Blind (Except For Moxifloxacin), Placebo And Active Controlled, Four Way Cross Over Study Investigating The Effect Of Single Therapeutic And Supra Therapeutic Doses Of Fedovapagon On The QT/QTC Interval In Healthy Volunteers Using Oral Moxifloxacin To Confirm Assay Sensitivity
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2016
At a glance
- Drugs Fedovapagon (Primary)
- Indications Nocturia
- Focus Adverse reactions
- Sponsors Vantia Therapeutics
- 05 Jan 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 17 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 17 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.